HNPCC (Lynch Syndrome): Differential Diagnosis, Molecular Genetics and Management - a Review

Hereditary Cancer in Clinical Practice

Jan Lubiński²  Trudy G Shaw¹  Jane F Lynch¹  Henry T Lynch¹ 

[1] Department of Preventive Medicine and Public Health, 2500 California Plaza, Omaha NE 68178, USA;International Hereditary Cancer Center, ul. Połabska 4, 70-115 Szczecin, Poland

关键词: Lynch syndrome;    colorectal cancer;    cancer genetics;    hereditary cancer;   

Others  :  1183604
DOI  :  10.1186/1897-4287-1-1-7

【 摘 要 】

HNPCC (Lynch syndrome) is the most common form of hereditary colorectal cancer (CRC), wherein it accounts for between 2-7 percent of the total CRC burden. When considering the large number of extracolonic cancers integral to the syndrome, namely carcinoma of the endometrium, ovary, stomach, hepatobiliary system, pancreas, small bowel, brain tumors, and upper uroepithelial tract, these estimates of its frequency are likely to be conservative. The diagnosis is based upon its natural history in concert with a comprehensive cancer family history inclusive of all anatomic sites. In order for surveillance and management to be effective and, indeed, lifesaving, among these high-risk patients, the linchpin to cancer control would be the physician, who must be knowledgeable about hereditary cancer syndromes, their molecular and medical genetics, genetic counseling, and, most importantly, the natural history of the disorders, so that the entirety of this knowledge can be melded to highly-targeted management.

   

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]International Agency for Research on Cancer: Globocan 2000. [http://www-dep.iarc.fr/globocan/globocan.html] webciteInternational Agency for Research on Cancer 2002.
• [2]Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
• [3]Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, Jhanwar S, Winawer S, Offit K, Luce MC, Kinzler KW, Vogelstein B: Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997, 17:79-83.
• [4]Herrera L, editors: Familial Adenomatous Polyposis. New York: Alan R. Liss, Inc; 1990.
• [5]Lynch HT, Smyrk TC: Classification of familial adenomatous polyposis: a diagnostic nightmare. Am J Hum Genet 1998, 62:1288-9.
• [6]Lynch HT, de la Chapelle A: Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999, 36:801-18.
• [7]Thorson A, Knezetic JA, Lynch HT: A century of progress in hereditary nonpolyposis colorectal cancer (Lynch syndrome). Dis Colon Rectum 1999, 42:1-9.
• [8]Warthin AS: Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch Intern Med 1913, 12:546-55.
• [9]Warthin AS: The further study of a cancer family. J Cancer Res 1925, 9:279-86.
• [10]Lynch HT, Shaw MW, Magnuson cW, Larsen AL, Krush AJ: Hereditary factors in cancer: study of two large Midwestern kindreds. Arch Intern Med 1966, 117:206-12.
• [11]Lynch HT, Krush AJ: Cancer family "G" revisited: 1895-1970. Cancer 1971, 27:1505-11.
• [12]Lynch HT, Smyrk T, Lynch JF: Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): historical journey from pedigree anecdote to molecular genetic confirmation. Oncology 1998, 55:103-8.
• [13]Yan H, Papadopoulos N, Marra G, Perrera C, Jiricny J, Boland CR, Lynch HT, Chadwick RB, de la Chapelle A, Berg K, Eshleman JR, Yuan W, Markowitz S, Laken SJ, Lengauer C, Kinzler KW, Vogelstein B: Conversion of diploidy to haploidy: individuals susceptible to multigene disorders may now be spotted more easily. Nature 2000, 403:723-4.
• [14]Lynch J: The genetics and natural history of hereditary colon cancer. Seminars in Oncology Nursing 1997, 13:91-8.
• [15]Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998, 338:1481-7.
• [16]Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Harkonen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Jarvinen H, Mecklin JP, Aaltonen LA, de la Chapelle A: Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000, 18:2193-200.
• [17]Lynch PM, Lynch HT, Harris RE: Hereditary proximal colonic cancer. Dis Colon Rectum 1977, 20:661-8.
• [18]Lynch HT, Krush AJ, Larsen AL: Heredity and multiple primary malignant neoplasms: six cancer families. Am J Med Sci 1967, 254:322-9.
• [19]Watson P, Lynch HT: The tumor spectrum in HNPCC. Anticancer Res 1994, 14:1635-40.
• [20]Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214-18.
• [21]Fusaro RM, Lynch HT, Pester J, Lynch PM: Torre's syndrome as phenotypic expression of cancer family syndrome. Arch Dermatol 1980, 116:986-7.
• [22]Lynch HT, Lynch PM, Pester JA, Fusaro RM: Sebaceous neoplasia and visceral cancer (Torre's syndrome) and its relationship to the cancer family syndrome. In Cancer-associated Genodermatoses. Edited by Lynch HT, Fusaro RM. New York: Van Nostrand Reinhold; 1982:366-93.
• [23]Lynch HT, Fusaro RM, Roberts L, Voorhees GJ, Lynch JF: Muir-Torre syndrome in several members of a family with a variant of the cancer family syndrome. Br J Dermatol 1985, 113:295-301.
• [24]Lynch HT, Fusaro RM: Muir-Torre syndrome: heterogeneity, natural history, diagnosis, and management. Prob Gen Surg 1993, 10:1-14.
• [25]Lynch HT, Leibowitz R, Smyrk T, Fusaro RM, Lynch JF, Smith A, Franklin B, Stella A, Liu B: Colorectal cancer and the Muir-Torre syndrome in a Gypsy family: a review. Am J Gastroenterol 1999, 94:575-80.
• [26]Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Green JS, Jass JR, Weber JL, Leach FS, Petersen GM, Hamilton SR, de la Chapelle A, Vogelstein B: Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993, 260:810-12.
• [27]Fusaro RM, Lemon SJ, Lynch HT: The Muir-Torre syndrome: a variant of hereditary nonpolyposis colorectal cancer syndrome. J Tumor Marker Oncol 1996, 11:19-31.
• [28]Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT: The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-5.
• [29]Vasen HFA, Watson P, Mecklin J-P, Lynch HT, ICG-HNPCC: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999, 116:1453-6.
• [30]Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S: A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda Guidelines. J Natl Cancer Inst 1997, 89:1758-62.
• [31]Standards for a model registry - recommendations for diagnosis, surveillance and treatment of selected CFS, EC Grant number QLRI-CT-1999-00063 [http://www.republika.pl/genetyka/standards.htm] webcite 2002.
• [32]Kladny J, Möslein G, Myrhøj T, Kurzawski G, Jakubowska A, Debniak T, Petriczko W, Kozlowski M, Al-Amawi T, Brzosko M, Flicinski J, Jawien A, Banaszkiewicz A, Richter P, Lubinski J: Nuclear pedigree criteria of suspected HNPCC. Her Can Clin Pract 2003, 1(1):34-8.
• [33]Rijcken FEM, Hollema H, Kleibeuker JH: Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut 2002, 50:382-6.
• [34]Jass JR, Stewart SM: Evolution of hereditary non-polyposis colorectal cancer. Gut 1992, 33:783-6.
• [35]Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A: Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut 2002, 50:228-34.
• [36]Cao Y, Pieretti M, Marshall J, Khattar NH, Chen B, Kam-Morgan L, Lynch H: Challenge in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the literature. Am J Gastroenterol 2002, 97:1823-7.
• [37]Lynch HT, Smyrk T, McGinn T, Lanspa S, Cavalieri J, Lynch J, Slominski-Castor S, Cayouette MC, Priluck I, Luce MC: Attenuated familial adenomatous polyposis (AFAP): a phenotypically and genotypically distinctive variant of FAP. Cancer 1995, 76:2427-33.
• [38]Nicolaides NC, Littman SJ, Modrich P, Kinzler KW, Vogelstein B: A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol 1998, 18:1635-41.
• [39]Wijnen J, de Leeuw W, Vasen H, Klift H, Moller P, Stormorken A, Meijers-Heijboer H, Lindhout D, Menko F, Vossen S, Moslein G, Tops C, Brocker-Vriends A, Wu Y, Hofstra R, Sijmons R, Cornelisse C, Morreau H, Fodde R: Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999, 23:142-4.
• [40]Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT: MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001, 19:4074-80.
• [41]Lynch HT: Family Information Service and hereditary cancer. Cancer 2001, 91:625-8.
• [42]Lynch HT: Dynamic Genetics Counseling for Clinicians. Springfield, Illinois: CC Thomas; 1969.
• [43]Lynch HT: Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum 1996, 39:109-10.
• [44]Church JM: Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med 1996, 28:479-82.
• [45]Vogelstein B, Kinzler KW, editors: The Genetic Basis of Human Cancer. New York: McGraw-Hill; 1998.
• [46]Polednak AP: Do physicians discuss genetic testing with family-history-positive breast cancer patients? Conn Med 1998, 62:3-7.
• [47]Cho MK, Sankar P, Wolpe PR, Godmilow L: Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet 1999, 83:157-63.
• [48]Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, Bacon JA, Booker SV, Parker RD, Hamilton SR: The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997, 336:823-7.
• [49]Aktan-Collan K, Mecklin JP, Jarvinen H, Nystrom-Lahti M, Peltomaki P, Soderling I, Uutela A, de la Chapelle A, Kaariainen H: Predictive genetic testing for hereditary non-polyposis colorectal cancer: Uptake and long-term satisfaction. Int J Cancer (Pred Oncol) 2000, 89:44-50.
• [50]Rex DK, Bond JH, Feld AD: Medical-legal risks of incident cancers after clearing colonoscopy. Am J Gastroenterol 2001, 96:952-7.
• [51]Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen GM, de la Chapelle A, Vogelstein B, Kinzler KW: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994, 371:75-80.
• [52]Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjld M, Fishel R, Kolodner R, Liskay RM: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994, 368:258-61.
• [53]Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75:1027-38.
• [54]Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, Yuasa Y: Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997, 57:3920-3.
• [55]Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T: Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997, 17:271-2.
• [56]Wu Y, Berends MJ, Sijmons RH, Mensink RG, Verlind E, Kooi KA, Sluis T, Kempinga C, Zee AG, Hollema H, Buys CH, Kleibeuker JH, Hofstra RM: A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001, 29:137-8.
• [57]Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, Lynch HT, Elliott RM, Collins FS: MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet 2000, 24:27-34.
• [58]de la Chapelle A: Microsatellite instability phenotype of tumors: genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 2002, 20:897-9.
• [59]Peltomäki P, Vasen HFA, International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 1997, 113:1146-58.
• [60]Jakubowska A, Gorski B, Kurzawski G, Debniak T, Hadaczek P, Cybulski C, Kladny J, Oszurek O, Scott RJ, Lubinski J: Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes. Hum Mutat 2001, 17:52-60.
• [61]Thibodeau SN, French AJ, Cunningham JM, Tester D, Burgart LJ, Roche PC, McDonnell SK, Schaid DJ, Vockley CW, Michels VV, Farr GH Jr, O'Connell MJ: Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998, 58:1713-18.
• [62]Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, Redston M, Thibodeau SN: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002, 20:1043-8.
• [63]Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, Kolodner RD, Fox E: Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002, 62:3485-92.
• [64]Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J: Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 2000, 36:49-54.
• [65]Levin B, Smith RA, Feldman GE, Colditz GA, Fletcher RH, Nadel M, Rothenberger DA, Schroy PS, Vernon SW, Wender R, National Colorectal Cancer Roundtable: Promoting early detection tests for colorectal carcinoma and adenomatous polyps. A framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer 2002, 95:1618-28.
• [66]Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. JAMA 1997, 277:915-19.
• [67]Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J, Radford-Smith G, Young J, Leggett B: Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998, 42:673-9.
• [68]Jass JR: Colorectal adenoma progression and genetic change: is there a link? Ann Med 1995, 27:301-6.
• [69]Park YJ, Shin K-H, Park J-G: Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 2000, 6:2994-8.
• [70]Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118:829-34.
• [71]Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S, Shashidharan M, Franklin B, Karr B, Thorson A, Lynch HT: Colorectal carcinoma survival among hereditary nonpolyposis colorectal cancer family members. Cancer 1998, 83:259-66.
• [72]Smyrk TC, Watson P, Kaul K, Lynch HT: Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal cancer. Cancer 2001, 91:2417-22.
• [73]Collins FS: Shattuck Lecture - Medical and societal consequences of the Human Genome Project. N Engl J Med 1999, 341:28-37.
• [74]David KL, Steiner-Grossman P: The potential use of tumor registry data in the recognition and prevention of hereditary and familial cancer. NY State J Med 1991, 91:150-2.
• [75]Lynch HT: Cancer and the family history trail. NY State J Med 1991, 91:145-7.
• [76]Houlston RS, Collins A, Slack J, Morton NE: Dominant genes for colorectal cancer are not rare. Ann Hum Genet 1992, 56:99-103.
• [77]Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N: Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001, 135:577-88.
• [78]Reyes CM, Allen BA, Terdiman JP, Wilson LS: Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002, 95:1848-56.
• [79]Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin J-P: Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996, 110:682-7.
• [80]Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77.
• [81]Branch P, Bicknell DC, Bowan A, Bodmer WF, Karran P: Immune surveillance in colorectal carcinoma. Nature Genet 1995, 9:231-2.
• [82]Jass JR, Cottier DS, Jeevaratnam P, Pokos V, Browett PJ: Pathology of hereditary nonpolyposis colorectal cancer with clinical and molecular genetic correlations. In New Strategies for Treatment of Hereditary Colorectal Cancer. Edited by Baba S. Tokyo: Churchill Livingstone; 1996:29-39.
• [83]Boman BM, Fry RD, Curran W, Deborah R, Cocker T, Kovatich A, Barusevicius A, Palazzo J, Cuesta K, Anne P, Melchert L, Fishel R, Mitchell E: Unique immunohistochemical features of MSI-classified tumors from HNPCC patients. Proceedings of ASCO 1999, 18:236a. (Abstract).